Explore more publications!

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines – PMI
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
Semaglutide Online Prescription Platform Releases Overview of Costs, Shipping, And Safety Protocols by Buy Stufz
Indianapolis Rehabilitation Hospital Appoints Dr. Emily Hogancamp as Medical Director
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO
Tucson Rehabilitation Hospital Names Dr. Peter Lux as Medical Director
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
Deadline Alert: Picard Medical, Inc. (PMI) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Charming Medical Ltd. of Class Action Lawsuit and Upcoming Deadlines - MCTA
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
InfusaLounge Marks New Era in North Texas Healthcare with Expansion into Integrative & Functional Medicine

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions